ComboMATCH Treatment Trials
ComboMATCH is a large precision medicine initiative with a coordinated set of clinical trials evaluating new anti-cancer drug combinations in select groups of adults and children with cancer. Each trial studies the effectiveness of a specific drug combination in a select group of patients (called a phase 2 trial design). The drug combinations are either two targeted therapies or chemotherapy with a targeted drug. Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that cause them to grow, divide, and spread.
Generally, this set of trials is for patients with advanced solid tumors. However, each trial has its own patient inclusion and exclusion criteria, such as the targeted tumor gene abnormalities, type of cancer, stage of disease, prior treatment, age of the patient, etc. Therefore, patients must first enroll in the ComboMATCH Patient Screening Trial (EAY191) to help determine eligibility for a treatment trial.
To learn more about a particular treatment trial, click the Trial ID in the table below.
| Trial ID / Lead Group | Drug Combination / Molecular Target(s) | Accrual Status |
|---|---|---|
| EAY191-E5 ECOG-ACRIN | Sotorasib and panitumumab in solid tumor cancers with KRAS G12C mutation | Recruiting (cohort 2) |
| EAY191-N4 NRG Oncology | Selumetinib and olaparib in ovarian or endometrial cancer with a RAS pathway mutation | Recruiting |
| EAY191-N5 NRG Oncology | Neratinib and palbociclib in HER2+ solid tumor cancers (except breast cancer) | Recruiting |
| EAY191-A3 Alliance | Binimetinib and palbociclib in ovarian, pancreatic, and other solid tumor cancers with RAS pathway mutations | Closed to accrual |
| EAY191-A6 Alliance | Binimetinib and chemotherapy in advanced biliary tract cancer with MAPK pathway mutation | Closed to accrual |
| EAY191-E4 ECOG-ACRIN | Nilotinib and chemotherapy (paclitaxel) in patients with prior taxane treatment | Closed to accrual |
| EAY191-N2 NRG Oncology | Binimetinib and fulvestrant in HR+, HER2-negative metastatic breast cancer with NF1 mutation | Closed to accrual |
| EAY191-S3 SWOG | Ipatasertib and chemotherapy (paclitaxel) in solid tumor cancers with AKT mutation | Closed to accrual |
ComboMATCH is an exciting system-wide collaboration. As shown in the table above, cooperative groups lead the various treatment trials with funding from the National Cancer Institute through its National Clinical Trials Network (NCTN). These groups include the Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network.
Questions?
- Patients interested in learning more about ComboMATCH should start by speaking with their doctor or healthcare team
- Reach out to the Contact Center at the National Cancer Institute, where trained specialists answer cancer-related questions in English and Spanish
- Study personnel with questions may send an email to the ComboMATCH Help Desk